Janux Therapeutics, INC 10-Q quarterly reports

Janux Therapeutics filed its Q1 2026 10-Q, detailing a net loss of $24.4 million and significant progress in its collaboration with Bristol-Myers Squibb.

Janux Therapeutics reported a net loss of $24.3 million for Q3 2025, driven by increased R&D, while advancing its TRACTr and ARM platforms and securing a $10 million Merck milestone.

Janux Therapeutics reported a significant increase in net loss driven by higher research and development expenses, while maintaining a strong cash position to fund its clinical-stage immunotherapy pipeline.

Janux Therapeutics reports a net loss of $23.5 million for Q1 2025, alongside updates on its clinical programs JANX007 and JANX008.

Janux Therapeutics' Q3 2024 report reveals increased collaboration revenue and strategic investments, alongside ongoing clinical development of its TRACTr platform.

Janux Therapeutics reports a significant increase in collaboration revenue and a reduced net loss for the second quarter of 2024, driven by a milestone achievement in its Merck partnership.

Janux Therapeutics reports a net loss of $14.8 million for the first quarter of 2024, alongside a significant increase in cash reserves following a substantial capital raise.